Oleoylethanolamide (OEA) supplementation effect on symptoms of dysmenorrhea

Oleoylethanolamide (OEA) supplementation effect on oxidative stress, prostaglandins, inflammatory factors and symptoms of primary dysmenorrhea in dormitory students in Qazvin University of Medical Sciences: A double-blind controlled clinical trial with placebo

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141025019669N14

Enrollment

Registered

2019-10-14

Start date

2019-10-12

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary dysmenorrhoea. Primary dysmenorrhea

Interventions

Intervention 1: Intervention group: Oleoylethanolamide, a capsule 120 mg per daily for two months, Manufacturer: Supplement Spot. Intervention 2: Control group: A daily placebo capsule containing whea

Eligibility

Sex/Gender

Female

Age

18 Years to 25 Years

Inclusion criteria

Inclusion criteria: Having primary dysmenorrhea Having regular menstruation between 35-21 days Single Having a body mass index below 30

Exclusion criteria

Exclusion criteria: Having secondary dysmenorrhea (endometriosis, adenomyosis, leiomyoma, uterine anomaly, Endometrial Polyps, ovarian cyst) Intake of antioxidant supplement in the last six months Intake of fatty acids supplements in the last six months

Design outcomes

Primary

Measure	Time frame
Total antioxidant capacity. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Malondialdehyde. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;E2 prostaglandin. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;F2a prostaglandin. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Inflammatory factors. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Duration of bleeding. Timepoint: Before the intervention and after the intervention. Method of measurement: According to a person's report by the questionnaire.;Pain duration. Timepoint: Before the intervention and after the intervention. Method of measurement: Duration of pain based on questionnaire.;Intensity of pain. Timepoint: Before the intervention and after the intervention. Method of measurement: Pain intensity according to the questionnaire.	—

Measure

Time frame

Total antioxidant capacity. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Malondialdehyde. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;E2 prostaglandin. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;F2a prostaglandin. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Inflammatory factors. Timepoint: Before the intervention and after the intervention. Method of measurement: Eliza.;Duration of bleeding. Timepoint: Before the intervention and after the intervention. Method of measurement: According to a person's report by the questionnaire.;Pain duration. Timepoint: Before the intervention and after the intervention. Method of measurement: Duration of pain based on questionnaire.;Intensity of pain. Timepoint: Before the intervention and after the intervention. Method of measurement: Pain intensity according to the questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Khadem Haghighian

Qazvin University of Medical Sciences

khademnut@yahoo.com+98 28 3333 6001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026